Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Spyre Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Spyre Therapeutics's regulatory disclosures and financial reporting.
Spyre Therapeutics, Inc. reported a net loss of $36.2 million for the quarter ended June 30, 2026 and $105.2 million for the first half of 2026, reflecting heavy investment in its immunology pipeline. Research and development expenses rose to $65.5 million in the quarter and $125.9 million year-to-date, driven by manufacturing and clinical trial spending in IBD and rheumatic disease programs.
Results include a $40.0 million quarterly gain ($70.0 million year-to-date) from milestone payments on the 2023 sale of pegzilarginase rights, partly offset by a $34.9 million increase in the contingent value right liability tied to those legacy assets. Liquidity strengthened through a $435.2 million April 2026 underwritten equity offering and $9.7 million of at-the-market sales; cash, cash equivalents and marketable securities totaled $1.1 billion as of June 30, 2026, which management expects to fund operations for at least one year. The company remains a clinical-stage biotech with no product revenue and states it will need additional financing to complete development and commercialization.
SYRE insider Scott Burrows filed a notice to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, related to an exercise of stock options for cash on 08/03/2026. The filing also lists sales during the prior three months, including 7,500 shares for $658,043.00 on 07/01/2026 under a 10b5-1 plan, 15,000 shares for $1,307,000.00 on 06/25/2026, and 7,500 shares for $532,948.25 on 06/01/2026.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows executed a pre-planned option exercise and share sale. On July 1, 2026, he exercised stock options covering 7,500 shares of common stock at $14.50 per share and sold 7,500 shares in open-market transactions at weighted average prices of $87.55 and $88.37. These trades were made under a Rule 10b5-1 trading plan adopted on November 10, 2025. After the transactions, he directly holds 97,994 common shares, plus 67,476 restricted stock units that vest in 2026 and 2027 and 352,357 remaining option shares expiring in 2033.
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan exercised options to acquire 8,334 shares of common stock at an exercise price of $27.46 per share, then sold the same 8,334 shares in open-market transactions.
The sales occurred on July 1, 2026 at weighted average prices of $87.52 and $88.34 per share, with individual trades ranging from $87.03 to $88.95, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. Following these transactions, Sloan reported no directly held common shares and 305,000 stock options outstanding, part of an option grant for 400,000 shares scheduled to fully vest over four years and expiring on October 1, 2034.
Spyre Therapeutics, Inc. Chief Executive Officer Cameron Turtle sold 15,000 shares of common stock in three open‑market transactions on July 1, 2026. The sales were executed at weighted average prices around $87–$89 per share and were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on June 20, 2025.
Following these transactions, Turtle holds 582,540 shares of Spyre Therapeutics common stock directly. This amount includes 72,623 shares that vest in monthly installments through November 2026, contingent on his continued service with the company.
SYRE submitted a Form 144 notice concerning the proposed sale of 45,000 shares of Common Stock. The filing shows these shares trace to previously exercised stock options dated 06/15/2023.
The excerpt also records two Rule 10b5-1 transactions by Cameron W. Turtle: 15,000 shares sold on 05/01/2026 for $1,070,506.50 and 15,000 shares sold on 06/01/2026 for $1,056,508.50. Shares outstanding are listed as 86,841,253 as of 07/01/2026.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows reported an exercise-and-sale transaction in company stock. On June 25, 2026, he exercised stock options to acquire 15,000 shares of common stock at an exercise price of $14.50 per share, then sold 15,000 shares in open-market transactions.
The sales comprised 10,000 shares at a weighted average price of $87.14 and 5,000 shares at $87.12, with actual trade prices ranging from $86.78 to $87.43. After these trades, he directly held 97,994 shares of common stock, including 67,476 restricted stock units that vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment.
Burrows also continues to hold a stock option originally covering 404,857 shares, with 359,857 option shares remaining after this 15,000‑share exercise. The option had been adjusted for a 1‑for‑25 reverse stock split and vests over several years based on continued employment.
Spyre Therapeutics filed a Form S-3ASR registering up to $500,000,000 of common stock for sale under an at-the-market Sales Agreement with TD Cowen. The registration also carries forward $36,550,000 of unsold securities from a prior registration under Rule 415(a)(6).
The prospectus shows the Nasdaq last sale price of the common stock at $88.67 per share on June 25, 2026, and states shares outstanding of 87,936,477 as of June 24, 2026. The prospectus supplement describes sales of common stock from time to time through TD Cowen as agent under an at-the-market program.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 notice for the sale of 15,000 shares of Common stock in connection with a stock option exercise to occur on 06/25/2026. The filing lists three prior sales by Scott Burrows totaling 27,500 shares on 04/01/2026, 05/01/2026, and 06/01/2026 with aggregate proceeds reported.
SYRE filing a notice of proposed sale of Common shares under Rule 144. The excerpt lists historical and planned dispositions tied to corporate events: 378,421 shares from a reverse merger (06/22/2023), 3,639,680 shares issued in exchange of Series A non-voting convertible preferred stock (04/25/2024), and 666,680 shares from conversion of Series B non-voting convertible preferred stock (06/23/2026). The cover lines show trade/agent details including 4,684,781 (numeric field) and an aggregate dollar figure $399,658,667.00 appearing in the excerpt.